DSIP & Sleep Peptides — Dosage Claims vs. the Actual Evidence

DSIP & Sleep Peptides · Evidence Review

By Jamie Walston · Beverly Hills Rejuvenation Center · Reviewed by the BHRC Clinical Team

No receptor. No gene. Four small human trials that stop in 1992, none of them using the route being sold. And an FDA advisory committee that looked at it this year and said no.

1. Where DSIP came from

DSIP was isolated from rabbit cerebral venous blood by the Schoenenberger–Monnier group in Basel in 1977; the nonapeptide sequence was published the following year. In rabbits it produced what the authors described as a highly specific delta and spindle EEG-enhancing effect, increasing mean delta activity by around 35%.

That is a real finding in rabbits. What happened next is the story.

“The link between DSIP and sleep has never been further characterized… the hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak… its natural occurrence and biological activity still remains obscure.”

That is from a 2006 critical appraisal in the Journal of Neurochemistry, titled — accurately — “Delta sleep-inducing peptide: a still unresolved riddle.” The same review notes something striking: slow-wave-sleep promotion in rabbits and rats was observed with certain artificial DSIP structural analogues — but not with DSIP itself.

2. The human trials, in full — there are only four

The complete human efficacy literature for DSIP is small enough to list.

The two studies with a proper placebo arm — Monti 1987 and Bes 1992 — found no significant difference and “little therapeutic benefit” respectively. The two that reported improvement were the two without adequate controls. That pattern is the classic signature of an effect that is not there.

The other proposed indications are thinner still. Narcolepsy: one single-subject case report, from 1984. Opioid withdrawal: two uncontrolled open-label studies, from 1984 and 1998. And the human literature effectively stops in 1992. There are no modern trials.

3. Is there a validated dose? No — and the reason matters

Every human study used the intravenous route at 25–30 nmol/kg. Every product sold and every protocol circulating online is subcutaneous.

The FDA’s own July 2026 briefing document states there are “no data for the proposed subcutaneous route for any condition.” Its assessment of the entire human evidence base was that findings were “inconclusive and at best preliminary,” and that “even when studies yielded positive treatment response, it seems unclear whether observed effects on sleep outcomes provided clinically significant improvement.” It cited small sample sizes and “lack of or poor selection of control groups.”

4. What the FDA actually did in 2026

The FDA’s additional findings are worth knowing: DSIP is not well-characterized, with inconsistent nomenclature and missing impurity, endotoxin and bioburden specifications. The free base has poor water solubility — about 0.5 mg/mL — which makes the proposed 1 mg/mL injectable formulation problematic on its face. Aggregation raises immunogenicity risk. Toxicology was insufficient. And the agency noted that “there are FDA-approved treatments with established efficacy for these medical conditions.”

On anti-doping: DSIP is not explicitly named on the 2026 WADA Prohibited List, but S0 captures any pharmacological substance with no current regulatory approval for human therapeutic use — which describes DSIP precisely. Athletes should treat it as prohibited. The absence of a name is not a safe harbour.

5. What actually has evidence for sleep

This is the useful half of the article, and it is where the guidelines are unambiguous.

Cognitive behavioural therapy for insomnia is first line. The American College of Physicians clinical practice guideline states it plainly: “ACP recommends that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder” — a strong recommendation with moderate-quality evidence. Medication should only be considered through shared decision-making, for short-term use, after CBT-I alone has been unsuccessful.

Note that sleep hygiene alone is not CBT-I — it is the weakest component of it. The active ingredients are stimulus control, sleep restriction and cognitive restructuring, and they require a structured program rather than a list of tips.

Melatonin deserves its own paragraph, because the evidence is much weaker than people assume. The American Academy of Sleep Medicine’s clinical practice guideline suggests “that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia… in adults” — a weak recommendation on very low quality evidence. Where melatonin does have a defensible role is circadian, not hypnotic: low doses of roughly 0.5–1 mg taken several hours before desired sleep onset shift circadian phase. The common 5–10 mg dose at bedtime is supraphysiologic and targets the wrong mechanism.

Magnesium, honestly: a meta-analysis of three randomized trials in 151 older adults found sleep onset latency reduced by about 17 minutes versus placebo (p = 0.0006), with total sleep time not significantly changed. The authors rated all trials at moderate-to- high risk of bias and the evidence low to very low quality, while noting magnesium is cheap and widely available. A seventeen-minute reduction from three small low-quality trials is the accurate description.

6. Where hormone care legitimately intersects with sleep

This is in-scope for a clinic like ours, and it is where we can actually help.

• Screen for obstructive sleep apnea before anything else. This is the single highest-yield action, and it is also a safety interlock for our own services — testosterone therapy can worsen OSA, and untreated OSA suppresses nocturnal growth hormone secretion. Treating “fatigue” hormonally while undiagnosed apnea continues is a clinical failure mode.
• Menopausal vasomotor symptoms. Nocturnal hot flashes fragment sleep, and hormone therapy improves sleep as a consequence of relieving them. That is a legitimate, well-supported pathway. Hormone therapy is indicated for vasomotor symptoms, not for insomnia as a primary complaint — and the distinction matters. Our menopause page covers it.
• Thyroid dysfunction — both hyper- and hypothyroidism disrupt sleep, and correcting genuine dysfunction is straightforward.
• A baseline panel is the unglamorous starting point. Advanced lab testing turns up treatable causes with reasonable frequency.

There is a certain irony here: the only genuinely controlled human sleep-EEG dataset among the peptides discussed in this space comes from GHRP-6 — not from the one actually marketed for sleep.

7. What we would tell you if you asked in person

Sleep is one of the highest-leverage things in health, and it is one of the few areas where the evidence-based answer is also the cheap one. DSIP is not it. There is no receptor, no gene, four small studies that stop in 1992, no data at all for the route being sold, and an advisory committee that looked at it this year and said no.

If you are sleeping badly, the sequence that actually helps is: rule out sleep apnea, treat anything genuinely dysfunctional that shows up on a panel, and do CBT-I. That is a less exciting answer than a peptide. It is also the one with a strong recommendation from a professional society behind it.

Questions we get asked

Keep reading

• DSIP — the BHRC page
• The 2026 FDA peptide reclassification, explained
• Provider-led peptide and hormone protocols
• Advanced lab testing — what a baseline panel covers
• Menopause and perimenopause at BHRC
• Men’s health — testosterone, candidacy and monitoring
• The BHRC longevity program

Book at any of our six locations

References

1. U.S. Food and Drug Administration — Pharmacy Compounding Advisory Committee briefing document — emideltide (DSIP), free base and acetate, July 2026. fda.gov
2. Kovalzon VM, Strekalova TV — Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem 2006;97(2):303–309. doi.org
3. Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M — The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflügers Arch 1978;376(2):119–129. doi.org
4. Qaseem A, Kansagara D, Forciea MA, et al. — Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;165(2):125–133. doi.org
5. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL — Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an AASM clinical practice guideline. J Clin Sleep Med 2017;13(2):307–349. doi.org
6. Mah J, Pitre T — Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis. BMC Complement Med Ther 2021;21:125. doi.org
7. U.S. Food and Drug Administration — July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee — agenda and materials. fda.gov
8. World Anti-Doping Agency — The 2026 Prohibited List — section S0, non-approved substances. wada-ama.org
9. Cornell Legal Information Institute — 21 CFR § 216.23 — the 503A bulks list. law.cornell.edu

Beverly Hills Rejuvenation Center. This content is for general education and does not create a physician-patient relationship or constitute medical advice. DSIP (emideltide) is not FDA-approved, does not appear on either FDA compounding bulks list, and was not recommended for listing by the FDA’s advisory committee in July 2026. This article is an evidence review and does not describe or recommend a protocol. Persistent insomnia should be evaluated by a clinician. Candidacy, dosing, results and pricing vary by person and are confirmed at a free consultation. Reviewed by the BHRC clinical team.